New York, NY - REMD Biotherapuetics, Inc,. was honored to co-host a diabetes focused Lyfebulb Connect event this past week at Le Colonial in New York City. Lyfebulb is a New York-based social, patient empowerment platform with a mission to connect people, inspire change, and impact lives. Lyfebulb Connect events touch on different disease areas and typically include a brief presentation from an expert in the field as well as testimonials from patients to discuss their personal experiences with the disease. The REMD team was thrilled to partner with such a dedicated organization and to have an opportunity to reveal their findings to such an engaged audience.
REMD CEO, Dr. Hai Yan, made an invigorating and exciting presentation regarding the company’s significant progress in diabetes research. Accompanying Dr. Yan were several members of his team, including Jim Zhiqing Shi, VP for Clinical Development, Jingang Wang, Senior Advisor, and Tom Tang, Clinical Advisor. Dr. Yan shared REMD’s work and discussed the current Phase 2 clinical development of REMD 477, an antibody targeting the glucagon receptor with the potential to improve glucose control in persons living with Type 1 and Type 2 diabetes. Coincidentally, the first patient in REMD Bio's clinical trial was dosed just two days before this Lyfebulb Connect event.
A senior medical internist, Dr. Zachary Bloomgarden, also presented at the event on the current status and future prospect of diabetes therapies, and praised REMD’s promising therapeutic candidate drug.
REMD looks forward to continuing a fruitful partnership with Lyfebulb.